Amplia Therapeutics (ASX:ATX) has announced that the Safety Review Committee of the ACCENT clinical trial has approved dose escalation of AMP945 and recruitment of another patient cohort in the trial, which is designed to identify the most suitable dose of AMP945 to combine with gemcitabine/nab-paclitaxel chemotherapy in patients with advanced pancreatic cancer.

The safety, pharmacokinetic and pharmacodynamic data has shown that dose escalation to a further cohort is warranted.

Amplia's CEO and Managing Director Dr Chris Burns commented on the news, saying they are "delighted" with the performance of AMP945.

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis.

Following the announcement, shares of Amplia Therapeutics were unchanged at $0.088.